Quince Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Benatti Luca | — | Sale | 50,000 | $3.47 | $173,500 | 39,179 | Dec 26, 2025 |
| Thye Dirk | CEO and CMO | Gift | 739,885 | — | — | 739,885 | Dec 10, 2025 |
| Hannah Brendan | CBO, COO & CCO | Option Exercise | 2,271 | $0.55 | $1,249 | 336,547 | Dec 5, 2025 |
| Hannah Brendan | CBO, COO & CCO | Award / Grant | 37,736 | $1.20 | $45,283 | 334,276 | Jun 18, 2025 |
| Ryan Charles S. | President | Award / Grant | 7,548 | $1.20 | $9,058 | 130,009 | Jun 18, 2025 |
| Thye Dirk | CEO and CMO | Award / Grant | 150,944 | $1.20 | $181,133 | 994,885 | Jun 18, 2025 |
| Benatti Luca | — | Other | 8,918 | — | — | 89,179 | Oct 23, 2024 |
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER | Purchase | 77,000 | $0.70 | $53,900 | 843,941 | Aug 29, 2024 |
| Ryan Charles S. | PRESIDENT | Purchase | 48,387 | $0.65 | $31,452 | 122,461 | Aug 20, 2024 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | Purchase | 3,424 | $0.60 | $2,054 | 265,695 | Aug 19, 2024 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | Option Exercise | 56,061 | $0.55 | $30,834 | 257,616 | Jun 4, 2024 |
| Thye Dirk | CHIEF EXECUTIVE OFFICER | Option Exercise | 90,531 | $0.55 | $49,792 | 539,442 | Jan 16, 2024 |
| Lamond David | — | Purchase | 22,627 | $1.00 | $22,627 | 2,324,918 | Dec 14, 2023 |
| Lamond David | — | Purchase | 19,123 | $1.01 | $19,314 | 2,279,664 | Dec 6, 2023 |
| Lamond David | — | Purchase | 14,378 | $0.98 | $14,090 | 2,193,539 | Nov 30, 2023 |
| Lamond David | — | Purchase | 41,026 | $1.31 | $53,744 | 2,138,135 | Aug 31, 2023 |
| Lamond David | — | Purchase | 24,766 | $1.29 | $31,948 | 2,097,109 | Aug 15, 2023 |
| Thye Dirk | Chief Executive Officer | Purchase | 88,000 | $1.26 | $110,880 | 448,911 | Aug 10, 2023 |
| Thye Dirk | Chief Executive Officer | Purchase | 80,000 | $1.24 | $99,200 | 360,911 | Aug 8, 2023 |
| Hannah Brendan | Chief Business Officer | Purchase | 71,762 | $1.22 | $87,550 | 201,555 | Aug 8, 2023 |
| McLoughlin Margaret | — | Purchase | 8,000 | $1.23 | $9,840 | 8,000 | Aug 8, 2023 |
| Monohon Ted | Chief Accounting Officer & VP | Sale | 1,871 | $0.98 | $1,834 | 27,440 | Mar 6, 2023 |
| Monohon Ted | Chief Accounting Officer & VP | Tax Withholding | 1,640 | $0.72 | $1,181 | 29,311 | Dec 5, 2022 |
| Monohon Ted | Chief Accounting Officer & VP | Tax Withholding | 1,520 | $1.64 | $2,493 | 30,951 | Sep 6, 2022 |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | Sale | 10,800 | $2.86 | $30,888 | 122,500 | Jun 6, 2022 |
| Holsinger Leslie | EVP, Preclinical Development | Tax Withholding | 10,920 | $2.86 | $31,231 | 148,080 | Jun 6, 2022 |
| Monohon Ted | Chief Accounting Officer & VP | Tax Withholding | 1,529 | $3.12 | $4,770 | 32,471 | Jun 6, 2022 |
| Hannah Brendan | Chief Business Officer | Award / Grant | 16,224 | — | — | 16,224 | May 19, 2022 |
| Lamond David | — | Award / Grant | 200,002 | — | — | 1,734,722 | May 19, 2022 |
| Low Philip S | — | Award / Grant | 63,974 | — | — | 63,974 | May 19, 2022 |
| Smith Karen L. | Chief Medical Officer | Award / Grant | 24,336 | — | — | 24,336 | May 19, 2022 |
| Thye Dirk | Chief Executive Officer | Award / Grant | 64,589 | — | — | 64,589 | May 19, 2022 |
| Hannah Brendan | Chief Business Officer | Award / Grant | 113,569 | — | — | 129,793 | May 19, 2022 |
| Thye Dirk | Chief Executive Officer | Award / Grant | 216,322 | — | — | 280,911 | May 19, 2022 |
| Smith Karen L. | Chief Medical Officer | Award / Grant | 170,354 | — | — | 194,690 | May 19, 2022 |
| Monohon Ted | Chief Accounting Officer & VP | Award / Grant | 34,000 | — | — | 34,000 | Mar 3, 2022 |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | Award / Grant | 140,000 | — | — | 140,000 | Mar 3, 2022 |
| LOWE CHRISTOPHER P. | Interim CEO, COO & CFO | Award / Grant | 175,000 | — | — | 265,000 | Mar 3, 2022 |
| Holsinger Leslie | EVP, Preclinical Development | Award / Grant | 155,500 | — | — | 159,000 | Mar 3, 2022 |
| Detke Michael J. | Chief Medical Officer | Award / Grant | 140,000 | — | — | 140,000 | Mar 3, 2022 |
| Lynch Casey | Chief Executive Officer | Option Exercise | 60,000 | $0.46 | $27,600 | 109,895 | Nov 18, 2021 |
| LOWE CHRISTOPHER P. | COO & Chief Financial Officer | Option Exercise | 30,000 | $2.23 | $66,900 | 90,000 | Nov 16, 2021 |
| Dominy Stephen S. | Chief Scientific Officer | Purchase | 763 | $14.40 | $10,987 | 1,217,086 | Nov 12, 2021 |
| McLoughlin Margaret | — | Option Exercise | 1,000 | $17.00 | $17,000 | 1,000 | Oct 8, 2021 |
| LOWE CHRISTOPHER P. | COO & Chief Financial Officer | Option Exercise | 4,963 | $54.85 | $272,221 | 64,963 | Oct 5, 2021 |
| LOWE CHRISTOPHER P. | COO & Chief Financial Officer | Sale | 2,330 | $96.32 | $224,426 | 33,177 | Aug 16, 2021 |
| McLoughlin Margaret | — | Sale | 48 | $98.90 | $4,747 | — | Aug 16, 2021 |
| Detke Michael J. | Chief Medical Officer | Option Exercise | 10,000 | $2.23 | $22,300 | 10,000 | Aug 10, 2021 |
| Detke Michael J. | Chief Medical Officer | Option Exercise | 17,400 | $2.23 | $38,802 | 17,400 | Jul 6, 2021 |
| McLoughlin Margaret | — | Sale | 100 | $55.73 | $5,573 | — | Jun 28, 2021 |